Prostate cancer is one of the most common cancers in the world. While many prostate cancers grow slowly and remain localized, other types are aggressive and spread quickly. That's why Dr. Carlos Vargas,

Thousands more men are having checks for prostate cancer since Sir Chris Hoy revealed he had been diagnosed with the disease and was terminally ill.

Prostate cancer is the second leading cause of death in men right behind heart disease. Patients with this cancer often don’t find out until the disease has advanced quite a bit. But there are some signs to watch for — and a new test to identify prostate cancer.

A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic benefits during treatment.

John Taylor, 69, from the Lake District, went to his GP twice complaining about needing to pass urine more than normal, but he was denied a PSA blood test. It was only at an annual check-up that he had a test,

With regard to the choice of bone-protecting agent, denosumab (Xgeva) improved bone density and reduced fracture risk in a placebo-controlled trial involving men with non-metastatic HSPC. Denosumab outperformed zoledronic acid for preventing SREs in men with metastatic castration-resistant prostate cancer.

Prostate cancer is a common cancer for men to be diagnosed with. While risk factors like age are unavoidable, there are other lifestyle changes men can make to potentially reduce their risk.

Prostate cancer tends to grow slowly. When caught in the earliest stages, the outlook is very good. The 5-year relative survival rate for prostate cancer that hasn’t spread, or has spread only ...

Researchers have found in a new BARCODE1 study that a polygenic risk score identified a higher proportion of clinically significant prostate cancer compared to PSA or MRI screening, which